Evaluation of Predictive Factors for Right Ventriculaire Dysfunction
NCT ID: NCT04596982
Last Updated: 2025-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18 participants
OBSERVATIONAL
2021-04-09
2023-10-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Preventive Left Ventricle Unloading After VA-ECMO for Refractory Cardiogenic Shock
NCT07027202
Echocardiographic Evaluation of RV Injury in the ICU
NCT05525936
Inter-observer Reproductibility of Visual Estimation of Left Ventricular Ejection Fraction in Critical Care
NCT04978389
Optimal ECMO Flow in the Critical Phase of Cardiogenic Shock to Optimize Peripheral Organ Perfusion and Myocardial Stress
NCT06936839
Simplified Assessment of Left Ventricular Systolic Function in Septic Shock Patients
NCT04963686
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For these reasons, in selected patients, a Left Ventricular Assist Device (LVAD) may be a bridge to transplantation or a way to improve the duration and quality of life of patients without a transplant project (destination therapy). Currently, about half of all heart transplants performed internationally are done in patients with left monoventricular assist, and in 2017 43% of implanted LVAD patients were in destination therapy.
For this reason, this observational study aims to describe the clinical, ultrasound and hemodynamic parameters of these patients and to establish a predictive score for right-sided dysfunction in a patient during the 30-day follow-up.
More precisely, during this study we will compare the clinical, ultrasound and hemodynamic parameters of these patients in order to establish a predictive score for right-sided dysfunction during :
* 48 hours on ECMO and IMPELLA (after IMPELLA® placement)
* 48 hours on IMPELLA alone following ECMO withdrawal.
* 48 hours under left monoventricular assistance
* At day 7 of the follow-up
* At day30 of the follow-up Patients who develop right heart failure within 48 hours of ECMO withdrawal after IMPELLA® placement will be compared to patients without right heart failure on demographic, clinical, history, treatment history, and cardiac echo and hemodynamic data at admission.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placement of IMPELLA®
ultrasound and hemodynamic parameters of patients in order to establish a predictive score for right-sided dysfunction after placement of IMPELLA®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. \- Patient under ECMO hospitalized in the medical intensive care unit or the surgical intensive care unit of the Groupement hospitalier Pitié-Salpêtrière, not weaned from ECMO, in whom it was decided at the multidisciplinary collegial meeting on assistance-transplantation to set up an IMPELLA before the implantation of left monoventricular assistance.
3. \- Patient who received informed information about the study and did not express opposition to participation in the research.
Special Cases :
o For patients who are unable to express their non-opposition, the investigator may request that of a relative of the patient.
or For patients under guardianship, their non opposition must be obtained in the presence of the guardian.
or For patients under guardianship, it is the legal guardian's non opposition that will be requested.
The modalities of information and obtaining the non opposition will be reported in the patient's medical file.
4. \- Patient affiliated or entitled to a French social security system -
Exclusion Criteria
2. \- Subject deprived of liberty by judicial decision
3. \- Pregnant or breastfeeding woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupement Hospitalier Pitié-Salpêtrière
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP200528
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.